Details for Patent: 11,020,393

Which drugs does patent 11,020,393 protect, and when does it expire?

Patent 11,020,393 protects RECORLEV and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 11,020,393

Title:	Methods of treating disease with levoketoconazole
Abstract:	Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.
Inventor(s):	Cohen; Fredric (Washington Crossing, PA)
Assignee:	Strongbridge Dublin Limited (Trevose, PA)
Application Number:	17/010,387
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,020,393

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes						DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE METFORMIN, MONITORING GLYCEMIA, KIDNEY FUNCTION AND VITAMIN B-12 AND ADJUSTING DOSAGE OF METFORMIN AS NEEDED

International Family Members for US Patent 11,020,393

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020232246
Brazil	112021017561
Canada	3132319